Posted on

The American Society of Transplant Surgeons Position Statement Supports Use of CareDx’s AlloSure Kidney for Organ Transplant Surveillance

Loading

MARCH, 07, 2023

Statement Also Supports Use of AlloSure Heart and AlloMap Heart  

BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the issuance of a new position statement by the American Society of Transplant Surgeons (ASTS) supporting the use of CareDx’s AlloSure® Kidney for organ transplant surveillance, and AlloSure Heart and AlloMap® Heart. Read the complete press release on CareDx.com.

Loading
Posted on

NYU Langone Raises the Bar as Top Transplant Program in New York for Quality & Volume

Loading


NYU Langone Health experts transplanted more lifesaving organs than any other New York transplant programs in 2022 while maintaining a high standard of care—setting the bar for the region in both volume and high-quality outcomes.

NYU Langone Transplant Institute teams performed 600 organ transplants last year, exceeding any single transplant center in the Northeast. Read more from NYU Langone Health News Hub.

Loading
Posted on

CareDx Key Supporter of the National Kidney Foundation’s Annual Kidney Patient Summit

Loading

MARCH, 01, 2023

BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that it is sponsoring the National Kidney Foundation (NKF) Annual Kidney Patient Summit taking place on Capitol Hill on March 1-2, 2023. Read the complete press release at CareDx.com.

Loading
Posted on

CareDx Showcases Latest Advancements in Cellular Transplant and Therapy Including Specialized Digital Health Solutions at the 2023 Tandem Meetings

Loading

FEBRUARY, 16, 2023

BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that it will be presenting its latest solutions to support the cellular transplant and therapy ecosystem at the 2023 Tandem Meetings |Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® taking place February 15-19 in Orlando, Florida.
Read the complete press release at CareDx.com.

Loading
Posted on

JACC Publication Guides Use of CareDx’s HeartCare Transplant Rejection Surveillance in Clinical Practice

Loading

JANUARY, 26, 2023

Guide Helps Transplant Centers Continue the Evolution from Endomyocardial Biopsies to Noninvasive Surveillance Using AlloMap GEP and AlloSure dd-cfDNA

BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Journal of the American College of Cardiology (JACC): Heart Failure has published a detailed guide1 to help clinicians transition from routine invasive endomyocardial biopsy (EMB) to a less invasive acute rejection monitoring protocol in clinical practice.

Loading
Posted on

Researchers confirm successful rehabilitation and recovery of human donor lungs previously deemed unfit for transplant

Loading

Study demonstrates that a novel technique for regenerating donor lungs can increase the number of organs available for life-saving transplantation

NEW YORK, Jan. 23, 2023 /PRNewswire/ — A novel method for supporting and recovering donor lungs outside the body shows potential to increase the number of organs available for transplant, according to a recent study published in The Journal of Heart and Lung Transplantation. Read the complete press release on Yahoo.com.

Loading
Posted on

Stanford Medicine teams awarded $18 million to improve kidney transplant and gene-editing techniques

Loading

The California Institute for Regenerative Medicine has funded Stanford Medicine projects to improve kidney transplantation and advance treatment for a rare genetic disease in children.

January 10, 2023 – By Erin Digitale

Physician-scientists at Stanford Medicine have received about $18 million from the California Institute for Regenerative Medicine for two projects to advance cutting-edge treatments for children: a clinical trial to allow kidney transplantation without the need for long-term immunosuppression, and a study of a gene-editing treatment for a rare disease that progressively damages the brain, heart and other organs. Read the full press release from the Stanford Medicine News Center here.

Loading
Posted on

UNOS Advances Plan to Restructure Transplant Network Governance to Best Serve Patients

Loading

Richmond, VA –News Direct– United Network for Organ Sharing

United Network for Organ Sharing (UNOS), the mission-driven non-profit that serves as the nation’s Organ Procurement and Transplantation Network (OPTN), has recommended a plan to the Health Resources and Services Administration (HRSA) to restructure the two organizations’ respective boards of directors and establish the OPTN as an independent non-profit entity. The move is intended to increase autonomy and transparency to better serve the nation’s transplant patients. Read more in Yahoo.com.

Loading
Posted on

CareDx Fosters Transplant Innovation as Distinguished Founder’s Circle Sponsor for the 23rd Annual American Society of Transplant Surgeons State of the Art Winter Symposium

Loading

CareDx Showcase Latest Innovations in Pre- and Post-Transplant Patient Care

BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced its leading participation and top spot, for the fourth consecutive year, as a Distinguished Founder’s Circle Sponsor for the 23rd Annual ASTS (American Society of Transplant Surgeons) State of the Art Winter Symposium, taking place January 12-15, in Miami, Florida.
Read the complete press release on CareDx.com.

Loading
Posted on

New ISHLT Guidelines Support Use of CareDx’s HeartCare Solutions, AlloMap and AlloSure, in Routine Monitoring of Heart Transplant Patients

Loading

DECEMBER, 21, 2022

ISHLT Guidelines Recommend Earlier Use of AlloMap Heart Starting 2 Months Post-Transplant Based on Strength of Clinical Studies

ISHLT Guidelines Recommend Remote Use of GEP and dd-cfDNA Heart Transplant Surveillance, as in HeartCare, May be Used to Reduce the Need for Biopsies and Hospital Visits

BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the publication1 of new guidelines by the International Society for Heart and Lung Transplantation (ISHLT) supporting the use of CareDx’s non-invasive molecular surveillance portfolio. Read the complete press release on CareDx.com.

Loading